News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
727,835 Results
Type
Article (47227)
Company Profile (298)
Press Release (680309)
Multimedia
Podcasts (80)
Webinars (15)
Section
Business (209467)
Career Advice (2193)
Deals (36084)
Drug Delivery (115)
Drug Development (82543)
Employer Resources (192)
FDA (16439)
Job Trends (15290)
News (353179)
Policy (33341)
Tag
Academia (2747)
Academic (2)
Accelerated approval (10)
Adcomms (25)
Allergies (97)
Alliances (51160)
ALS (113)
Alzheimer's disease (1493)
Antibody-drug conjugate (ADC) (158)
Approvals (16429)
Artificial intelligence (339)
Autoimmune disease (29)
Automation (19)
Bankruptcy (367)
Best Places to Work (11831)
BIOSECURE Act (20)
Biosimilars (125)
Biotechnology (200)
Bladder cancer (94)
Brain cancer (34)
Breast cancer (370)
Cancer (2922)
Cardiovascular disease (219)
Career advice (1843)
Career pathing (33)
CAR-T (196)
CDC (36)
Cell therapy (524)
Cervical cancer (23)
Clinical research (67689)
Collaboration (1056)
Company closure (3)
Compensation (691)
Complete response letters (25)
COVID-19 (2704)
CRISPR (60)
C-suite (340)
Cystic fibrosis (114)
Data (3033)
Decentralized trials (2)
Denatured (35)
Depression (64)
Diabetes (349)
Diagnostics (6583)
Digital health (23)
Diversity (10)
Diversity, equity & inclusion (48)
Drug discovery (144)
Drug pricing (131)
Drug shortages (29)
Duchenne muscular dystrophy (133)
Earnings (88380)
Editorial (43)
Employer branding (25)
Employer resources (163)
Events (117388)
Executive appointments (873)
FDA (18118)
Fibrodysplasia Ossificans Progressiva (2)
Friedreich's ataxia (4)
Frontotemporal dementia (9)
Funding (969)
Gene editing (137)
Generative AI (25)
Gene therapy (393)
GLP-1 (833)
Government (4664)
Grass and pollen (4)
Guidances (182)
Healthcare (19230)
HIV (41)
Huntington's disease (32)
IgA nephropathy (41)
Immunology and inflammation (155)
Immuno-oncology (9)
Indications (39)
Infectious disease (2881)
Inflammatory bowel disease (154)
Inflation Reduction Act (12)
Influenza (63)
Intellectual property (122)
Interviews (346)
IPO (16821)
IRA (47)
Job creations (3850)
Job search strategy (1572)
Kidney cancer (13)
Labor market (57)
Layoffs (519)
Leadership (21)
Legal (8090)
Liver cancer (80)
Longevity (11)
Lung cancer (411)
Lymphoma (210)
Machine learning (11)
Management (62)
Manufacturing (404)
MASH (93)
Medical device (13629)
Medtech (13634)
Mergers & acquisitions (19989)
Metabolic disorders (876)
Multiple sclerosis (99)
NASH (22)
Neurodegenerative disease (122)
Neuropsychiatric disorders (33)
Neuroscience (2193)
NextGen: Class of 2025 (6725)
Non-profit (4658)
Now hiring (49)
Obesity (448)
Opinion (237)
Ovarian cancer (103)
Pain (111)
Pancreatic cancer (122)
Parkinson's disease (190)
Partnered (22)
Patents (306)
Patient recruitment (169)
Peanut (52)
People (59731)
Pharmaceutical (72)
Pharmacy benefit managers (21)
Phase I (21090)
Phase II (29806)
Phase III (22178)
Pipeline (1655)
Policy (210)
Postmarket research (2643)
Preclinical (9208)
Press Release (72)
Prostate cancer (142)
Psychedelics (40)
Radiopharmaceuticals (259)
Rare diseases (473)
Real estate (6241)
Recruiting (73)
Regulatory (23107)
Reports (60)
Research institute (2486)
Resumes & cover letters (375)
Rett syndrome (9)
RNA editing (9)
RSV (51)
Schizophrenia (90)
Series A (167)
Series B (113)
Service/supplier (14)
Sickle cell disease (63)
Special edition (19)
Spinal muscular atrophy (151)
Sponsored (33)
Startups (3795)
State (2)
Stomach cancer (15)
Supply chain (77)
Tariffs (58)
The Weekly (43)
Vaccines (813)
Venture capital (56)
Weight loss (276)
Women's health (49)
Worklife (18)
Date
Today (83)
Last 7 days (351)
Last 30 days (1831)
Last 365 days (31672)
2025 (17213)
2024 (35966)
2023 (40876)
2022 (51938)
2021 (56512)
2020 (54925)
2019 (47664)
2018 (35956)
2017 (33111)
2016 (32695)
2015 (38792)
2014 (32401)
2013 (27552)
2012 (29823)
2011 (30561)
2010 (29055)
Location
Africa (795)
Alabama (63)
Alaska (7)
Arizona (253)
Arkansas (14)
Asia (39942)
Australia (6570)
California (7539)
Canada (2379)
China (684)
Colorado (330)
Connecticut (321)
Delaware (193)
Europe (86935)
Florida (1127)
Georgia (258)
Hawaii (2)
Idaho (60)
Illinois (656)
India (29)
Indiana (370)
Iowa (18)
Japan (232)
Kansas (111)
Kentucky (31)
Louisiana (15)
Maine (64)
Maryland (1042)
Massachusetts (5648)
Michigan (264)
Minnesota (472)
Mississippi (3)
Missouri (92)
Montana (28)
Nebraska (25)
Nevada (82)
New Hampshire (68)
New Jersey (2113)
New Mexico (30)
New York (2122)
North Carolina (1129)
North Dakota (10)
Northern California (3311)
Ohio (240)
Oklahoma (16)
Oregon (34)
Pennsylvania (1626)
Puerto Rico (17)
Rhode Island (36)
South America (1174)
South Carolina (34)
South Dakota (1)
Southern California (2817)
Tennessee (127)
Texas (1147)
United States (28112)
Utah (225)
Virginia (189)
Washington D.C. (77)
Washington State (642)
West Virginia (4)
Wisconsin (80)
727,835 Results for "gb sciences inc".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Press Releases
Kexing Biopharm’s GB18 project received clearance of IND application from NMPA and FDA
May 29, 2025
·
2 min read
Press Releases
Annexon Highlights Pivotal Data on First Potential Targeted Therapy for Guillain-Barré Syndrome (GBS) and Showcases New GBS Education Campaign at American Academy of Neurology (AAN) 2025 Annual Meeting
April 8, 2025
·
9 min read
Press Releases
Annexon Announces Presentations on the Clinical Advancement of Tanruprubart as the First Potential Targeted Therapy for Guillain-Barré Syndrome (GBS) at the 2025 PNS Meeting
May 12, 2025
·
6 min read
Press Releases
Annexon Showcases Tanruprubart Data Demonstrating Improved Clinical Outcomes in Guillain-Barré Syndrome (GBS) at 2025 Peripheral Nerve Society (PNS) Annual Meeting
May 20, 2025
·
8 min read
Press Releases
Annexon Highlights Leadership in Advancing Clinical Research and Education for Guillain-Barré Syndrome (GBS) at American Academy of Neurology (AAN) 2025 Annual Meeting
April 4, 2025
·
5 min read
Biotech Bay
Annexon Biosciences to Host Conference Call and Webcast to Discuss GBS Phase 3 DataCall scheduled for Tuesday, June 4, 2024 at 8:30 a.m. ET
Annexon, Inc. today announced that it will host a conference call and webcast on Tuesday, June 4, 2024, at 8:30 a.m. ET to discuss GBS phase 3 data.
June 3, 2024
·
1 min read
Drug Development
Galecto Announces First Patient Dosed in an Investigator-Initiated Phase 2 Trial of GB1211 in Combination with Pembrolizumab
Galecto, Inc. announced that the first patient has been enrolled in an investigator-initiated Phase 2 trial to evaluate GB1211, Galecto’s first-in-class, oral small molecule galectin-3 inhibitor candidate, at the Earle A. Chiles Research Institute, a division of Providence Cancer Institute in Portland, Oregon, USA.
May 1, 2024
·
7 min read
Policy
Cepheid Receives FDA Clearance for Xpert® Xpress GBS
Cepheid announced that it has received clearance from the U.S. Food and Drug Administration for Xpert® Xpress GBS, a dual-target molecular diagnostic test for the qualitative intrapartum detection of Group B Streptococcus.
March 11, 2024
·
3 min read
Press Releases
CV Sciences, Inc. Reports First Quarter 2025 Financial Results
May 15, 2025
·
13 min read
Job Trends
Massachusetts’ Life Sciences Job Growth Flattens After 10+ Years of Increases: Report
Massachusetts’ life sciences jobs grew by just 0.03% in 2024, according to a new MassBioEd report. Still, the report found encouraging signs for the industry, noting it’s expected to grow by 11.6% by 2029, adding an estimated 16,633 net new positions.
June 4, 2025
·
3 min read
·
Angela Gabriel
1 of 72,784
Next
